In line with this efficacy of Moxetumomab in immunocompromised xenografts of human lymphoma, HF injections were more active than bolus doses in our h/mCD22+, primary murine lymphoma, thus indicating functional similarity of human CD22+ lymphoma and the newly established h/mCD22+ murine lymphoma. This evidence concerns the gene CD22 and lymphoma.